Citigroup
ELVN icon

Citigroup’s Enliven Therapeutics ELVN Stock Holding History

Citigroup’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56M Buy
30,712
+16,011
+109% +$680K ﹤0.01% 3120
2026
Q1 		$576K Sell
14,701
-3,788
-20% -$105K ﹤0.01% 3460
2025
Q4 		$285K Buy
18,489
+6,743
+57% +$134K ﹤0.01% 3836
2025
Q3 		$240K Sell
11,746
-6,393
-35% -$129K ﹤0.01% 3917
2025
Q2 		$364K Sell
18,139
-12,700
-41% -$240K ﹤0.01% 3799
2025
Q1 		$607K Sell
30,839
-2,709
-8% -$58.3K ﹤0.01% 3574
2024
Q4 		$755K Buy
33,548
+4,650
+16% +$121K ﹤0.01% 3564
2024
Q3 		$738K Buy
28,898
+18,296
+173% +$424K ﹤0.01% 3488
2024
Q2 		$248K Buy
10,602
+2,769
+35% +$58.3K ﹤0.01% 3783
2024
Q1 		$138K Buy
7,833
+427
+6% +$6.55K ﹤0.01% 4164
2023
Q4 		$102K Buy
7,406
+4,059
+121% +$49.7K ﹤0.01% 4192
2023
Q3 		$45.7K Sell
3,347
-7,476
-69% -$126K ﹤0.01% 4172
2023
Q2 		$221K Sell
10,823
-440
-4% -$8.89K ﹤0.01% 3847
2023
Q1 		$247K Buy
+11,263
New +$229K ﹤0.01% 3602
2021
Q2 		– Sell
-127
Closed -$4K – 6188
2021
Q1 		$4K Sell
127
-227
-64% -$11.5K ﹤0.01% 5936
2020
Q4 		$31K Buy
354
+294
+490% +$24.7K ﹤0.01% 6366
2020
Q3 		$5K Sell
60
-108
-64% -$9.74K ﹤0.01% 6996
2020
Q2 		$19K Buy
+168
New +$18.8K ﹤0.01% 6650

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Citigroup's ELVN Position: Q2 2026 in Review

Citigroup increased its Enliven Therapeutics (ELVN) stake by 109% in Q2 2026, buying an estimated $680K and bringing the position to 30,712 shares worth $1.56M. The position accounts for ﹤0.01% of the portfolio, ranked #3120.

Citigroup first reported a position in ELVN in Q2 2020 and has held it in 18 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Citigroup held 30,712 shares of Enliven Therapeutics worth $1.56M as of Q2 2026.
  • Citigroup bought 16,011 Enliven Therapeutics shares in Q2 2026, an estimated $680K.
  • Enliven Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3120 holding.
  • Citigroup first reported a position in Enliven Therapeutics in Q2 2020 and has held it in 18 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.